US · Healthcare · Biotechnology
EPS came in at -0.71 against a street estimate of -0.55 — a miss of 29.1%.
with an average price target of $24.73.
| Fund | Stake |
|---|---|
| Cormorant Asset Management, LLC | 22.30% |
| Deerfield Management Co | 6.09% |
| Omega Fund Management LLC | 4.10% |
| Alphabet Inc | 3.52% |
| EcoR1 Capital, LLC | 3.52% |
| Wellington Management Company LLP | 3.48% |
| Enavate Sciences GP, LLC | 3.28% |
| Citadel Advisors Llc | 3.27% |
| Document | Date |
|---|---|
| Company announcement · Q3 2026 BRIDGEBIO ONCOLOGY THERAPEUTICS, INC. - 8-K SUMMARY HEADLINE NUMBERS • Company: BridgeBio Oncology Therapeutics, Inc. (Ticker: BBOT, Nasdaq) • Repor | 2026-09-08 |
| Quarterly report · Q2 2026 BRIDGEBIO ONCOLOGY THERAPEUTICS, INC. — 10-Q SUMMARY (Q2 2026) HEADLINE NUMBERS • Cash Position: $54.1 million in cash and cash equivalents as of Ju | 2026-08-11 |
| Results announced · Q3 2026 BBOT Q2 2026 FINANCIAL SUMMARY HEADLINE NUMBERS • Cash Position: $344.1 million in cash, cash equivalents and marketable securities as of June 30, 2 | 2026-08-11 |
| Board / officer change · Q2 2026 BRIDGEBIO ONCOLOGY THERAPEUTICS, INC. - 8-K SUMMARY HEADLINE NUMBERS • Total shares entitled to vote at Annual Meeting: 80,112,725 • Shares present | 2026-06-22 |
| Quarterly report · Q1 2026 BRIDGEBIO ONCOLOGY THERAPEUTICS, INC. — 10-Q SUMMARY Quarter Ended March 31, 2026 --- HEADLINE NUMBERS • Cash & Securities Position: $388.9 million | 2026-05-12 |
| Results announced · Q2 2026 BBOT Q1 2026 FINANCIAL RESULTS SUMMARY HEADLINE NUMBERS • Cash position: $388.9 million as of March 31, 2026 • Cash runway expected into 2028 • Q1 2 | 2026-05-12 |
| Proxy statement · Q2 2026 BRIDGEBIO ONCOLOGY THERAPEUTICS, INC. — 2026 PROXY SUMMARY --- WHAT SHAREHOLDERS ARE VOTING ON • Proposal 1: Election of Two Class I Directors — Vo | 2026-04-28 |
| Annual report FY2025 BRIDGEBIO ONCOLOGY THERAPEUTICS, INC. — 10-K SUMMARY HEADLINE NUMBERS • Company Status: Clinical-stage biotechnology company; completed SPAC merger | 2026-03-05 |
Readable in the app.
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for BridgeBio Oncology Therapeutics, Inc. — free to start.
Google PlayApp StoreData updated 2026-09-18.